John Tomtishen

John Tomtishen is a cell therapy industry veteran and recognized CMC leader within biopharmaceutical manufacturing having served in diverse business and technical roles throughout his career. John is currently the SVP & General Manager of Cellares' IDMO business where he is facilitating Cell Shuttle market adoption with various partners to transform the cell therapy manufacturing paradigm. Earlier in his career, John played pivotal roles in the filing and approval of the first CAR-T cell therapy, Kymriah™ while at Novartis, and the clinical development and BLA filing of Carvykti™ at Legend Biotech. John serves as the CMC Committee Chair with the American Society of Gene and Cell Therapy (ASGCT), the Manufacturing Advisory Committee Co-Chair with BioNJ, and is a member of the Cell Therapy Advisory Committee with the Alliance for Regenerative Medicine (ARM).